Health Catalyst (HCAT) EBITDA (2018 - 2026)

Health Catalyst has reported EBITDA for 9 years, with the latest figure at -$102.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 518.41% year-over-year to -$102.5 million; the trailing twelve-month figure through Mar 2026 stood at -$231.8 million (down 328.67% YoY), and the FY2025 full-year result was -$145.9 million, down 155.86% from the prior year.
• EBITDA for Q1 2026 stood at -$102.5 million, down from -$82.1 million in the prior quarter.
• The five-year high for EBITDA was -$10.6 million in Q3 2024, with the low at -$102.5 million in Q1 2026.
• Historically, EBITDA has averaged -$32.3 million across 5 years, with a median of -$29.7 million in 2023.
• Annual changes were most pronounced in 2024 — EBITDA jumped 59.56% — and 2026, when it sank 518.41%.
• Health Catalyst's EBITDA stood at -$33.5 million in 2022, then climbed by 11.51% to -$29.7 million in 2023, then jumped by 52.16% to -$14.2 million in 2024, then tumbled by 478.03% to -$82.1 million in 2025, then retreated by 24.85% to -$102.5 million in 2026.
• The last three EBITDA figures came in at -$102.5 million (Q1 2026), -$82.1 million (Q4 2025), and -$13.7 million (Q3 2025), per Business Quant data.